In Brief: Pfizer earnings, NAD decision, DXM bill, FDA warning, regulatory agenda
This article was originally published in The Tan Sheet
Executive Summary
Pfizer’s OTC pain sales drop; NAD Procera AVH claims to FTC; House introduces DXM bill; FDA warns medical food firm; Regulatory Agenda pushes back OTC actions; meetings address terrorism-related food adulteration; and more news In Brief.